Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
11
×
cancer
11
×
life sciences
merck
11
×
national blog main
new york blog main
raleigh-durham blog main
san diego blog main
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york top stories
raleigh-durham top stories
san diego top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
pfizer
bristol-myers squibb
clinical trials
deals
eli lilly
moderna
amgen
fda
startups
abbvie
alzheimer's disease
What
bio
roundup
companies
drug
life
moves
science
week
annual
buy
cancer
clinical
conference
debut
esmo
european
growing
medical
nash
new
news
oncology
patients
physicians
society
talk
treatment
acquisitions
adding
advantages
aims
alliance
approval
approved
arena’s
ash
bar
barcelona
becker
biggest
Language
unset
Current search:
merck
×
cancer
×
biotech
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front